Safety Study of SEA-CD40 in Cancer Patients

NCT02376699 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

159

Enrollment

INDUSTRY

Sponsor class

Stopped Study closed due to portfolio prioritization

Conditions

Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Hodgkin Disease
Lymphoma
Lymphoma, B-Cell
Lymphoma, Follicular
Lymphoma, Large B-Cell, Diffuse
Melanoma
Neoplasm Metastasis
Neoplasms, Head and Neck
Neoplasms, Squamous Cell
Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer Metastatic
Non-small Cell Carcinoma
Squamous Cell Cancer
Squamous Cell Carcinoma
Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Neoplasm
Lymphoma, Non-Hodgkin
Pancreatic Adenocarcinoma

Interventions

DRUG: Intravenous (IV) SEA-CD40
DRUG: Pembrolizumab
DRUG: Subcutaneous (SC) SEA-CD40
DRUG: Gemcitabine
DRUG: Nab-paclitaxel

Sponsor

Seagen Inc.

Collaborators

[object Object]